Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 39 min ago
Peer-reviewedCC BYClinical Case Reports

PD‐1 Inhibitor (Sintilimab) Combined With Chemotherapy as Neoadjuvant Therapy in Advanced Ovarian Cancer: A Case Report

  • Wang Zhenyan1
  • Wang Yan1
  1. 1Department of Gynecology The Affiliated Hospital of Qingdao University Qingdao City Shandong Province China
Read full textPDFDOICite

Abstract

In a patient with advanced ovarian cancer showing limited response to paclitaxel–carboplatin, adding sintilimab was associated with R0 cytoreduction and sustained disease‐free status during olaparib–bevacizumab maintenance. This case provides a rationale for further investigation of PD‐1 blockade as neoadjuvant therapy in carefully selected patients with suboptimal response to platinum–taxane chemotherapy.

Related

  1. Analysis of Laryngoscopic Image Differences in Different Responses to Neoadjuvant Immunotherapy Combined With Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma.
    Wen Gao, Zhuoheng Liu, Lifei Feng +6
    Laryngoscope investigative otolaryngologyPeer-reviewedCC BY-NC-NDFull textMedical imaging & radiologyEurope PMCPMC
  2. Evaluation of the efficacy and safety of different cycles of neoadjuvant chemotherapy combined with immunotherapy in locally advanced esophageal squamous cell carcinoma: a multi-center, real-world study.
    Huilai Lv, Zuopeng Wang, Chunyong Su +11
    World journal of surgical oncologyPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCPMC
  3. Neoadjuvant chemotherapy in locally advanced colon cancer: lessons from the NeoCol trial and the limits of anatomical risk stratification.
    Mohamed Alkashty
    Annals of coloproctologyPeer-reviewedCC BY-NCFull textOncologyEurope PMC
  4. Relative change rate of neutrophil-to-albumin ratio (ΔNAR) during neoadjuvant chemotherapy predicts axillary pathological complete response in locally advanced breast cancer
    Yujie Zhao, Yuxiang Deng, Weicai Chen +4
    Gland SurgeryPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. Efficacy and safety of neoadjuvant chemotherapy with toripalimab in locally advanced nasopharyngeal carcinoma: a phase II trial and biological correlate analysis
    Caineng Cao, Yulu Shen, Mengyun Qiang +9
    eClinicalMedicinePeer-reviewedCC BY-NC-ND 4.0General medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{zhenyan2026inhibitor,
  title = {{PD‐1 Inhibitor (Sintilimab) Combined With Chemotherapy as Neoadjuvant Therapy in Advanced Ovarian Cancer: A Case Report}},
  author = {Wang Zhenyan and Wang Yan},
  journal = {Clinical Case Reports},
  year = {2026},
  month = oct,
  doi = {10.1002/ccr3.73598},
  url = {https://doi.org/10.1002/ccr3.73598},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - PD‐1 Inhibitor (Sintilimab) Combined With Chemotherapy as Neoadjuvant Therapy in Advanced Ovarian Cancer: A Case Report
AU  - Wang Zhenyan
AU  - Wang Yan
PY  - 2026
DA  - 2026/10/23
JO  - Clinical Case Reports
DO  - 10.1002/ccr3.73598
UR  - https://doi.org/10.1002/ccr3.73598
AB  - In a patient with advanced ovarian cancer showing limited response to paclitaxel–carboplatin, adding sintilimab was associated with R0 cytoreduction and sustained disease‐free status during olaparib–bevacizumab maintenance. This case provides a rationale for further investigation of PD‐1 blockade as neoadjuvant therapy in carefully selected patients with suboptimal response to platinum–taxane chemotherapy.
SN  - 2050-0904
ER  -